cortistatin a
Description
cortistatin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
cortistatin A : A member of the class of cortistatins that is substituted by hydroxy groups at positions 1 and 2, a dimethylamino group at the 3alpha position and an isoquinolin-7-yl group at the 17 position, with double bonds at the 9-11 and 10-19 positions (the 1R,2R,17beta enantiomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11561907 |
CHEMBL ID | 4080906 |
CHEBI ID | 67171 |
SCHEMBL ID | 12431713 |
MeSH ID | M0524992 |
Synonyms (25)
Synonym |
---|
cortistatin a |
cortistatine a |
882976-95-6 |
unii-6vg04xov89 |
10a,12a-epoxybenzo(4,5)cyclohept(1,2-e)indene-7,8-diol, 9-(dimethylamino)-1,2,3,3a,4,7,8,9,10,11,12,12b-dodecahydro-3-(7-isoquinolinyl)-3a-methyl-, (3s,3ar,7r,8r,9s,10ar,12as,12br)- |
6vg04xov89 , |
(3s,3ar,7r,8r,9s,10ar,12as,12br)-9-(dimethylamino)-1,2,3,3a,4,7,8,9,10,11,12,12b-dodecahydro-3-(7-isoquinolinyl)-3a-methyl-10a,12a-epoxybenzo(4,5)cyclohept(1,2-e)indene-7,8-diol |
17-epi-cortistatin a |
cortistatin a [mi] |
(1r,2r,3s,5r,8alpha,17beta)-3-(dimethylamino)-17-(isoquinolin-7-yl)-5,8-epoxy-9,19-cyclo-9,10-secoandrosta-9(11),10-diene-1,2-diol |
(+)-cortistatin a |
CHEBI:67171 |
(1r,2r,3s,5r)-3-(dimethylamino)-17beta-(isoquinolin-7-yl)-5,8alpha-epoxy-9,19-cyclo-9,10-secoandrosta-9(11),10-diene-1,2-diol |
c1i , |
SCHEMBL12431713 |
DTXSID10468617 |
gtpl9885 |
(1r,2r,3s,5r,17alpha)-3-(dimethylamino)-17-(isoquinolin-7-yl)-5,8-epoxy-9,19-cyclo-9,10-secoandrosta-9(11),10-diene-1,2-diol |
bdbm50248631 |
Q5173335 |
CHEMBL4080906 , |
(3s,3ar,7r,8r,9s,10ar,12as,12br)-9-(dimethylamino)-3-(isoquinolin-7-yl)-3a-methyl-1,2,3,3a,4,7,8,9,10,11,12,12b-dodecahydro-10a,12a-epoxybenzo[4,5]cyclohepta[1,2-e]indene-7,8-diol |
(1s,2r,5s,6r,12r,13r,14s,16r)-14-(dimethylamino)-5-isoquinolin-7-yl-6-methyl-19-oxapentacyclo[14.2.1.01,9.02,6.011,16]nonadeca-8,10-diene-12,13-diol |
10a,12a-epoxybenzo[4,5]cyclohept[1,2-e]indene-7,8-diol, 9-(dimethylamino)-1,2,3,3a,4,7,8,9,10,11,12,12b-dodecahydro-3-(7-isoquinolinyl)-3a-methyl-, (3s,3ar,7r,8r,9s,10ar,12as,12br)- |
AKOS040745681 |
Research Excerpts
Overview
Cortistatin A (CA) is a highly selective inhibitor of the Mediator kinases CDK8 and CDK19.
Excerpt | Reference | Relevance |
---|---|---|
"Cortistatin A (CA) is a highly selective inhibitor of the Mediator kinases CDK8 and CDK19. " | ( Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics. Dowell, RD; Ebmeier, CC; Lee, T; Odell, AT; Old, WM; Pelish, HE; Poss, ZC; Shair, MD; Taatjes, DJ; Tangpeerachaikul, A, 2016) | 2.11 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Individually increasing or decreasing the expression of these transcription factors suppressed AML cell growth, providing evidence that leukaemia cells are sensitive to the dosage of SE-associated genes." | ( Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Arefolov, A; Armstrong, SA; Banka, D; Bronson, RT; Caruso, BT; Christie, AL; Da Silva, DH; Du, K; Ebmeier, CC; Fadeyi, O; Jestel, A; Kohl, NE; Krivtsov, AV; Kung, AL; Lemieux, ME; Liau, BB; Myers, AG; Nitulescu, II; Pelish, HE; Poss, ZC; Schneider, EV; Shair, MD; Si, C; Taatjes, DJ; Tangpeerachaikul, A; Zou, G, 2015) | 0.42 |
Drug Classes (3)
Class | Description |
---|---|
cortistatins | Any member of a class of steroidal alkaloids obtained from the marine sponge Corticium simplex, with a basic skeleton that is (5R,8beta)-5,8-epoxy-9,19-cyclo-9,10-secoandrostane, bearing a dimethylamino substituent at position 3 and an isoquinolin-7-yl or isoquinolin-7-yl-derived substituent at position 17. They selectively inhibit proliferation of human umbilical vein endothelial cells (HUVECs). |
diol | A compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols. |
secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (6)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Rho-associated protein kinase 2 | Homo sapiens (human) | IC50 (µMol) | 0.2200 | 0.0002 | 0.5780 | 10.0000 | AID1388659 |
Cyclin-C | Homo sapiens (human) | IC50 (µMol) | 0.0050 | 0.0050 | 0.6792 | 5.9000 | AID1388656 |
Cyclin-dependent kinase 8 | Homo sapiens (human) | IC50 (µMol) | 0.0085 | 0.0034 | 1.0275 | 5.9000 | AID1388656; AID1474304 |
Rho-associated protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 0.2500 | 0.0004 | 0.8549 | 10.0000 | AID1388658 |
Cyclin-dependent kinase 19 | Homo sapiens (human) | IC50 (µMol) | 0.0100 | 0.0050 | 0.4085 | 2.2000 | AID1388657 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Activation Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Rho-associated protein kinase 2 | Homo sapiens (human) | Kd | 0.2200 | 0.0002 | 2.7105 | 56.0660 | AID1613748 |
cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | Kd | 3.5000 | 0.0039 | 2.9479 | 23.2450 | AID1613749 |
Cyclin-dependent kinase 8 | Homo sapiens (human) | Kd | 0.0170 | 0.0014 | 1.2908 | 8.0000 | AID1613744 |
Rho-associated protein kinase 1 | Homo sapiens (human) | Kd | 0.2500 | 0.0003 | 1.7555 | 13.4620 | AID1613747 |
Cyclin-dependent kinase 19 | Homo sapiens (human) | Kd | 0.0100 | 0.0015 | 1.9204 | 7.2000 | AID1613746 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (131)
Molecular Functions (29)
Ceullar Components (37)
Bioassays (28)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1345316 | Human Rho associated coiled-coil containing protein kinase 1 (Rho kinase) | 2009 | Angewandte Chemie (International ed. in English), , Volume: 48, Issue:47 | Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. |
AID1345673 | Human cyclin dependent kinase 19 (CDK8 subfamily) | 2009 | Angewandte Chemie (International ed. in English), , Volume: 48, Issue:47 | Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. |
AID1345661 | Human cyclin dependent kinase 8 (CDK8 subfamily) | 2009 | Angewandte Chemie (International ed. in English), , Volume: 48, Issue:47 | Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. |
AID1345327 | Human Rho associated coiled-coil containing protein kinase 2 (Rho kinase) | 2009 | Angewandte Chemie (International ed. in English), , Volume: 48, Issue:47 | Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. |
AID1613749 | Binding affinity to wild-type partial length human PKACalpha (G10 to F351 residues) expressed in bacterial expression system by Kinomescan assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1613750 | Antiproliferative activity against VEGF-stimulated HUVEC | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1388660 | Growth inhibition of human SKNO1 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1613751 | Cytotoxicity against NHDF cells | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1388657 | Inhibition of CDK19 (unknown origin) in presence of [gamma33P]ATP by radiometric method | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1474304 | Inhibition of CDK8 (unknown origin) assessed as reduction in RNAP2 C-terminal domain phosphorylation | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives. |
AID1474305 | Antitumor activity against human SET2 cells implanted in AML patients assessed as reduction in tumor volume administered intraperitoneally relative to control | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives. |
AID1613744 | Binding affinity to wild-type partial length human CDK8 (M1 to T360 residues) expressed in bacterial expression system by Kinomescan assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1388662 | Growth inhibition of human SET2 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1613747 | Binding affinity to wild-type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Kinomescan assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1388661 | Growth inhibition of human RS4:11 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1388658 | Inhibition of ROCK1 (unknown origin) | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1388664 | Growth inhibition of human MV4-11 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1613746 | Binding affinity to wild-type partial length human CDK11 (M1 to N360 residues) expressed in bacterial expression system by Kinomescan assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1388663 | Growth inhibition of human MOLM14 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1388667 | Growth inhibition of human TF1 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1388655 | Antitumor activity against human SET2 cells xenografted in SCID Beige mouse assessed as tumor growth inhibition at 0.16 mg/kg, ip qd measured on day 33 relative to control | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1388668 | Growth inhibition of human HCT116 cells after 7 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1388659 | Inhibition of ROCK2 (unknown origin) | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1613748 | Binding affinity to wild-type partial length human ROCK2 (M1 to T431 residues) expressed in mammalian expression system by Kinomescan assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1388665 | Growth inhibition of human UKE1 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1613752 | Selectivity index, ratio of IC50 for NHDF cells to IC50 for VEGF-stimulated HUVEC | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
AID1388656 | Inhibition of CDK8/CCNC (unknown origin) using RBER-IRStide as substrate in presence of [gamma33P]ATP by radiometric method | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
AID1388666 | Growth inhibition of human MEG01 cells after 10 days by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (29)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (27.59) | 29.6817 |
2010's | 21 (72.41) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 30.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.69) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (10.34%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 26 (89.66%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |